# Molecular Disease Characterization Initiative (MDCI)

> **NCT04772053** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 6 (actual)

## Conditions studied

- Lung Cancer, Non-Small Cell
- Neoplasms

## Interventions

- **PROCEDURE:** Tumor biopsy

## Key facts

- **NCT ID:** NCT04772053
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-25
- **Primary completion:** 2022-11-15
- **Final completion:** 2022-11-15
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** The study was terminated for reasons pertaining to feasibility
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04772053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04772053, "Molecular Disease Characterization Initiative (MDCI)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04772053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*